



(11) **EP 2 344 672 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
24.12.2014 Bulletin 2014/52

(45) Date of publication and mention
of the grant of the patent:
12.11.2014 Bulletin 2014/46

(21) Application number: **09816583.0**

(22) Date of filing: **25.09.2009**

(51) Int Cl.:
C12Q 1/68 (2006.01) C12N 15/11 (2006.01)

(86) International application number:
PCT/US2009/005318

(87) International publication number:
WO 2010/036353 (01.04.2010 Gazette 2010/13)

(54) **GENETIC MARKERS FOR OPTIMIZING TREATMENT FOR SCHIZOPHRENIA**

GENETISCHE MARKER ZUR OPTIMIERUNG EINER SCHIZOPHRENIEBEHANDLUNG

MARQUEURS GÉNÉTIQUES POUR OPTIMISER LE TRAITEMENT DE LA SCHIZOPHRÉNIE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR**

(30) Priority: **25.09.2008 US 100176 P**

(43) Date of publication of application:
20.07.2011 Bulletin 2011/29

(60) Divisional application:
14192641.0

(73) Proprietor: **SureGene LLC**
Louisville, KY 40299 (US)

(72) Inventors:
• **BRENNAN, Mark, David**
Jeffersonville, Indiana 47130 (US)
• **RAMSEY, Timothy, Lynn**
Shelbyville, KY 40065 (US)

(74) Representative: **Coehn, Markus**
Fish & Richardson P.C.
Mies-van-der-Rohe-Strasse 8
80807 München (DE)

(56) References cited:
WO-A1-2008/055341 US-A1- 2008 206 768

- **LEUCHT S ET AL: "What does the PANSS mean?", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 79, no. 2-3, 15 November 2005 (2005-11-15), pages 231-238, XP027835369, ISSN: 0920-9964 [retrieved on 2005-11-15]**
- **RILEY BRIEN ET AL: "Molecular genetic studies of schizophrenia", EUROPEAN JOURNAL OF HUMAN GENETICS, KARGER, BASEL, CH, vol. 14, no. 6, 1 June 2006 (2006-06-01), pages 669-680, XP002519427, ISSN: 1018-4813, DOI: 10.1038/SJ.EJHG.5201571**
- **BERTOLINO ET AL: "COMT Val<158>Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 95, no. 1-3, 29 August 2007 (2007-08-29), pages 253-255, XP022217143, ISSN: 0920-9964, DOI: 10.1016/J.SCHRES.2007.06.014**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 344 672 B8